Losartan and its interaction with copper(II): biological effects
Susana B Etcheverry1, Evelina G Ferrer, Luciana Naso
1Centro de Química Inorgánica, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, 47 y 115 (1900) La Plata, Argentina.
Bioorganic & Medicinal Chemistry
|July 27, 2007
Summary
This study characterizes a new copper(II) complex of the antihypertensive drug Losartan. The Losartan copper(II) complex exhibits antioxidant properties and differential toxicity to tumoral cells compared to Losartan alone.
Area of Science:
- Pharmaceutical Chemistry
- Coordination Chemistry
- Biomedical Science
Background:
- Losartan is a widely used antihypertensive drug.
- Copper complexes can exhibit unique biological activities.
- Understanding Losartan's coordination chemistry is important for novel drug development.
Purpose of the Study:
- To synthesize and characterize a novel copper(II) complex with Losartan.
- To investigate the antioxidant and cytotoxic properties of the Losartan-copper(II) complex.
- To evaluate the complex's effects on osteoblast-like cells.
Main Methods:
- Vibrational spectroscopy (FTIR and Raman) for structural analysis.
- Electron Paramagnetic Resonance (EPR) spectroscopy for impurity detection.
- In vitro cell culture assays to assess proliferation, morphology, and toxicity.
Main Results:
- The copper(II) complex was synthesized and characterized, revealing a dimeric structure with a tetragonal distorted metal center and a monomeric impurity.
- The Losartan ligand coordinated to copper(II) via the tetrazolate nitrogen atoms.
- The complex demonstrated superoxide dismutase mimetic activity and selective toxicity towards tumoral cells.
Conclusions:
- The novel Losartan-copper(II) complex possesses distinct structural and biological properties.
- The complex shows potential as an antioxidant agent with enhanced cytotoxic effects on tumoral cells.
- Further research into Losartan-metal complexes may yield new therapeutic agents.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Dose-Response Relationship: Potency and Efficacy
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...